In this study, simple, fast and reliable cyclic voltammetry (CV), linear sweep voltammetry (LSV), square wave voltammetry (SWV) and differential pulse voltammetry (DPV) methods were developed and validated for determination of bosentan in pharmaceutical preparations. The proposed methods were based on electrochemical oxidation of bosentan at platinum electrode in acetonitrile solution containin...

in this study, simple, fast and reliable cyclic voltammetry (cv), linear sweep voltammetry (lsv), square wave voltammetry (swv) and differential pulse voltammetry (dpv) methods were developed and validated for determination of bosentan in pharmaceutical preparations. the proposed methods were based on electrochemical oxidation of bosentan at platinum electrode in acetonitrile solution containin...

In this study, simple, fast and reliable cyclic voltammetry (CV), linear sweep voltammetry (LSV), square wave voltammetry (SWV) and differential pulse voltammetry (DPV) methods were developed and validated for determination of bosentan in pharmaceutical preparations. The proposed methods were based on electrochemical oxidation of bosentan at platinum electrode in acetonitrile solution containin...

conclusions we observed acceptable results regarding both efficacy and safety with 62.5 mg of bosentan, twice daily in this group of patients. further clinical trials investigating pah with lower dosages of bosentan may be warranted. results no adverse drug reaction was observed during the follow-up. clinical worsening occurred in six (14%) patients, at least one year after treatment, two of th...

BACKGROUND/AIMS We assessed the efficacy and safety of bosentan in patients with pulmonary arterial hypertension (PAH). METHODS We surveyed randomized controlled trials (RCTs) of the efficacy and safety of bosentan in patients with PAH using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis of RCTs was performed to determine treatment efficacy and sa...

BACKGROUND/AIMS Both endothelin-1 (ET-1) and the renin-angiotensin system (RAS) may play important roles in renal fibrosis in the obstructed kidney. However, there have been few clear demonstrations of a relationship between their activation and additive or synergistic roles in renal fibrosis. We investigated the protective roles and relationship between renal RAS and ET-1 in unilateral uretera...

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Exposure to bosentan was lower in paediatric pulmonary arterial hypertension (PAH) patients treated with the marketed adult formulation at a dose of about 2 mg kg(-1) when compared with adult PAH patients. * In healthy adult subjects, bosentan pharmacokinetics are less than dose-proportional at doses of >or=500 mg. WHAT THIS STUDY ADDS * The pharmaco...

The absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan was investigated in healthy male subjects by administration of 14C-labeled compound. Four subjects received a single oral dose of 500 mg of bosentan (3.7 MBq), and four other subjects received a single i.v. dose of 250 mg of bosentan (3.7 MBq). Radioactivity and concentrations of bosentan and its metabolite...

BACKGROUND Endothelin-1, the most potent vasoconstrictor known, is produced in septic states and may be involved in the pathophysiology of the deteriorated splanchnic circulation seen in septic shock. AIMS To elucidate the capability of bosentan, a non-peptide mixed endothelin receptor antagonist, to attenuate splanchnic blood flow disturbances and counteract intestinal mucosal acidosis in en...

RATIONALE A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and health-related quality of life were observed. OBJECTIVES To demonstrate that bosentan delays IPF worsening or death. METHODS Prospective, randomized (2:1), double-blind, placebo-controlled, event-driven, parallel-g...